Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meredith M Regan

Showing results (1-10 of 259) with videos related to

Pageof 26
Sort By:
Breast (Edinburgh, Scotland)|December 17, 2019
Risk stratification according to stage and pathologyMeredith M Regan
Breast (Edinburgh, Scotland)|August 10, 2015
Predicting benefit of endocrine therapy for early breast cancerMeredith M Regan
Cancer Treatment and Research|July 14, 2009
Statistical issues and challengesMeredith M Regan
Breast (Edinburgh, Scotland)|November 27, 2021
Accelerating progress to innovation for patients: Trial design and risk stratificationMeredith M Regan
Breast (Edinburgh, Scotland)|January 11, 2022
Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?Meredith M Regan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2019
Reply to K.-D. Yu et alThomas Ruhstaller, Meredith M Regan
Breast (Edinburgh, Scotland)|October 4, 2005
Predicting response to systemic treatments: learning from the past to plan for the futureMeredith M Regan, Richard D Gelber
Breast (Edinburgh, Scotland)|July 5, 2017
Trial designs and results supporting treatment de-escalation and escalationMeredith M Regan, William T Barry
Breast (Edinburgh, Scotland)|August 28, 2007
Using clinical trial data to tailor adjuvant treatments for individual patientsMeredith M Regan, Richard D Gelber,
The New England Journal of Medicine|October 2, 2014
Exemestane with ovarian suppression in premenopausal breast cancerOlivia Pagani, Meredith M Regan, Prudence A Francis, et al.
Pageof 26

Showing results (1-10 of 259) with videos related to

Sort By:
Pageof 26
Breast (Edinburgh, Scotland)|December 17, 2019
Risk stratification according to stage and pathologyMeredith M Regan
Breast (Edinburgh, Scotland)|August 10, 2015
Predicting benefit of endocrine therapy for early breast cancerMeredith M Regan
Cancer Treatment and Research|July 14, 2009
Statistical issues and challengesMeredith M Regan
Breast (Edinburgh, Scotland)|November 27, 2021
Accelerating progress to innovation for patients: Trial design and risk stratificationMeredith M Regan
Breast (Edinburgh, Scotland)|January 11, 2022
Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?Meredith M Regan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2019
Reply to K.-D. Yu et alThomas Ruhstaller, Meredith M Regan
Breast (Edinburgh, Scotland)|October 4, 2005
Predicting response to systemic treatments: learning from the past to plan for the futureMeredith M Regan, Richard D Gelber
Breast (Edinburgh, Scotland)|July 5, 2017
Trial designs and results supporting treatment de-escalation and escalationMeredith M Regan, William T Barry
Breast (Edinburgh, Scotland)|August 28, 2007
Using clinical trial data to tailor adjuvant treatments for individual patientsMeredith M Regan, Richard D Gelber,
The New England Journal of Medicine|October 2, 2014
Exemestane with ovarian suppression in premenopausal breast cancerOlivia Pagani, Meredith M Regan, Prudence A Francis, et al.
Pageof 26